Peramivir and its use in H1N1 influenza

Castillo, Rocío Paricio del; Holland, Louis E.; Boltz, David A.

doi:10.1358/dot.2010.46.6.1459659

Cited by 16 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peramivir showed low oral bioavailability. Expecting effects in other drug delivery routes, trials were designed to ascertain whether intravenously or intramuscularly administered peramivir can reduce viral titer, and to assess the time to alleviate influenza symptoms 21. The drug was developed as an intravenously administered preparation.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Safety and efficacy of peramivir for influenza treatment

Hata¹,

Akashi-Ueda²,

Takamatsu³

et al. 2014

DDDT

View full text Add to dashboard Cite

ObjectiveThis report presents a review of the efficacy and safety of peramivir, a neuraminidase inhibitor that was granted Emergency Use Authorization by the US Food and Drug Administration (FDA) from October 23, 2009 to June 23, 2010 during the 2009 H1N1 pandemic.MethodsLiterature was accessed via PubMed (January 2000–April 2014) using several search terms: peramivir; BCX-1812; RWJ 270201; H1N1, influenza; antivirals; and neuraminidase inhibitors. The peramivir manufacturers, Shionogi and Co Ltd and BioCryst Pharmaceuticals, were contacted to obtain unpublished data and information presented at recent scientific meetings. Information was obtained from the Centers for Disease Control and Prevention (CDC) and from US FDA websites. English-language and Japanese-language reports in the literature were reviewed and selected based on relevance, along with information from the CDC, US FDA, and the drug manufacturers.ResultsWe obtained eleven clinical trial reports of intravenous peramivir, two of which described comparisons with oseltamivir. Seven of nine other recently reported published studies was a dose–response study. Clinical reports of critically ill patients and pediatric patients infected with pandemic H1N1 described that early treatment significantly decreased mortality. Peramivir administered at 300 mg once daily in adult patients with influenza significantly reduces the time to alleviation of symptoms or fever compared to placebo. It is likely to be as effective as other neuraminidase inhibitors.ConclusionAlthough peramivir shows efficacy for the treatment of seasonal and pH1N1 influenza, it has not received US FDA approval. Peramivir is used safely and efficiently in hospitalized adult and pediatric patients with suspected or laboratory-confirmed influenza. Peramivir might be a beneficial alternative antiviral treatment for many patients, including those unable to receive inhaled or oral neuraminidase inhibitors, or those requiring nonintravenous drug delivery.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Many peramivir recipients treated under the EUA were critically ill and at risk for influenza-related complications. Detailed reviews for the trials conducted during this period are available in the literature 21,22,28,29…”

Section: Resultsmentioning

confidence: 99%

Safety and efficacy of peramivir for influenza treatment

Hata¹,

Akashi-Ueda²,

Takamatsu³

et al. 2014

DDDT

View full text Add to dashboard Cite

show abstract

“…6). However, a relatively low bioavailability of less than 12% was observed for compound (13), which was even more reduced with analogues (10)(11)(12). An improved subnanomolar N1 inhibition was found for the ring isomer (14), whereby the authors argue that the Fig.…”

Section: Structure and Replication Of Influenza Virusesmentioning

confidence: 99%

Strategies for the Development of Influenza Drugs: Basis for New Efficient Combination Therapies

Steinmetzer¹,

Hardes²,

Böttcher‐Friebertshäuser³

et al. 2014

Topics in Medicinal Chemistry

View full text Add to dashboard Cite

Only four drugs are approved for the specific treatment of acute influenza infections worldwide. These drugs address either the viral neuraminidase or the M2-channel but suffer from poor efficacy and the rapid emergence of drug resistances. Some additional drugs are launched in few countries, but their efficacy is relatively low and often limited to certain influenza strains. Ideally, new drugs should possess a broad potency against all influenza viruses and be less susceptible to the development of resistances. The propagation cycle of the influenza virus offers many possibilities for the development of new anti-influenza drugs. Various compounds addressing viral targets reached clinical development, from which the most-advanced candidate is the polymerase inhibitor favipiravir. A promising strategy could be also the inhibition of host targets and signaling pathways, e.g., by already approved kinase inhibitors, anti-inflammatory drugs, or immunomodulatory agents. However, the benefit of these agents has to be demonstrated in controlled clinical trials. A broader arsenal of approved drugs will offer the possibility for more efficient combinatorial therapies in the future. The first proof of concept studies for such multiple drug therapies in infected mice revealed beneficial effects. Moreover, this strategy should reduce the rapid emergence of resistant influenza strains.

show abstract

“…Peramivir, an NAI administered by the intravenous route, has been developed, and clinical trials have demonstrated the safety of this option. Japan has recently licensed peramivir under the name Rapiacta ® [58,59].…”

Section: Antiviral Drugs and Their Limitationsmentioning

confidence: 99%

Immunomodulatory therapy for severe influenza

Darwish

Mubareka

Liles

2011

Expert Review of Anti-infective Therapy

116

110

View full text Add to dashboard Cite

Influenza A virus is a significant cause of morbidity and mortality worldwide. Severe influenza is recognized as a clinical syndrome, characterized by hyperinduction of proinflammatory cytokine production, otherwise known as hypercytokinemia or a 'cytokine storm'. Research focused on therapeutics to modulate influenza virus-induced inflammation is currently underway. In this review, we discuss the limitations of current antiviral drug treatment strategies, describe the influenza viral and host pathogenicity determinants, and present the evidence supporting the use of immunomodulatory therapy to target the host inflammatory response as a means to improve clinical outcome in severe influenza. We then review the experimental data on investigational immunomodulatory agents targeting the host inflammatory response in severe influenza, including anti-TNF therapy, statins, glucocorticoids, cyclooxygenase-2 inhibitors, macrolides, peroxisome proliferator-activated receptor agonists, AMP-activated protein kinase agonists and high mobility group box 1 antagonists. We then conclude with a rationale for the use of mesenchymal stromal (stem) cells and angiopoietin-1 therapy against deleterious influenza-induced host responses that mediate end-organ injury and dysfunction.

show abstract

Peramivir and its use in H1N1 influenza

Cited by 16 publications

References 0 publications

Safety and efficacy of peramivir for influenza treatment

Safety and efficacy of peramivir for influenza treatment

Strategies for the Development of Influenza Drugs: Basis for New Efficient Combination Therapies

Immunomodulatory therapy for severe influenza

Contact Info

Product

Resources

About